NASDAQ · IBRX
ImmunityBio, Inc.
$8.74-$0.07 (-0.79%)
ImmunityBio, Inc.’s quoted price sits in the upper half of its reported 52-week range, 29.69% below the high.
Loading market information…
NASDAQ · NBTX · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Nanobiotix S.A.’s quoted price sits in the lower half of its reported 52-week range, 40.85% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Nanobiotix S.A.’s next earnings report is currently expected on Apr 27, 2027, with estimated earnings per share of $0.06. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Nanobiotix S.A.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Nanobiotix S.A. is a clinical-stage biotechnology firm focused on developing innovative therapeutic solutions for cancer. The company's leading experimental drug, NBTXR3, is a sterile aqueous suspension comprising crystalline hafnium oxide nanoparticles. This treatment is currently undergoing development for its potential application in a broad spectrum of cancers, including soft tissue sarcoma, various head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has established a strategic collaboration with LianBio for the development and commercialization of NBTXR3 within key Asian markets, specifically Greater China, South Korea, Singapore, and Thailand. Founded in 2003, the company's main operations are situated in Paris, France.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:18 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2023 | Apr 24, 2024 | -$0.33+60.4% vs estimate | $36.20M |
|---|
| Q2 2023 | Nov 13, 2023 | -$0.87-47.6% vs estimate | $3.59M-9.09% vs estimate |
|---|
| Q4 2022 | Mar 28, 2023 | -$0.95 | $1.86M |
|---|
THE ANALYST VIEW
4 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 1 contributors · Median target $38.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$8.74-$0.07 (-0.79%)
ImmunityBio, Inc.’s quoted price sits in the upper half of its reported 52-week range, 29.69% below the high.
$21.48-$0.27 (-1.24%)
Tyra Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 47.16% below the high.
$14.15-$0.17 (-1.19%)
Syndax Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.7% below the high.
$10.56-$0.16 (-1.49%)
Kura Oncology, Inc.’s quoted price sits in the lower half of its reported 52-week range, 24.03% below the high.
$15.95+$0.22 (+1.4%)
ArriVent BioPharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.48% below the high.
$8.65-$0.02 (-0.23%)
Candel Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 38.21% below the high.
$7.98-$0.15 (-1.78%)
Immix Biopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 47.15% below the high.
$18.57+$0.21 (+1.14%)
Nuvectis Pharma, Inc.’s quoted price sits in the upper half of its reported 52-week range, 36.58% below the high.
